References
- SantosJAlarcãoJFareleiraFVaz-CarneiroACostaJTapentadol for chronic musculoskeletal pain in adultsCochrane Database Syst Rev20155CD00992326017279
- UeberallMAMueller-SchwefeGHEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observationsJ Pain Res201691001102027881925
- SterneJAHernánMAReevesBCROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ2016355i491927733354
- BaronRLikarRMartin-MolaEEffectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 studyPain Pract201616558059926095455
Reference
- UeberallMAMueller-SchwefeGHEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observationsJ Pain Res201691001102027881925